THE GENIUS BEHIND GUIDELINES

Carmina A. Delos Reyes, MD
Editor-in-Chief, PIDSP Journal

Medical guidelines are documents containing recommendations which can be used in clinical practice. They are intended to help physicians make informed decisions on diagnostic or treatment dilemmas and help achieve the best outcomes for patients.

Medical guidelines are not made overnight. Members of the guidelines development committee, composed of a multidisciplinary panel of experts from key groups, are carefully chosen to produce a high quality scientific document. This is achieved through a transparent, evidence-based decision-making process that is labor intensive and rigorous. This ensures that guidelines are sound, credible and at par with international standards.

The process starts by defining the topic and scope for guideline development. Key issues and questions regarding the topic are drafted. Review of questions, literature search, evidence reviews, and committee discussions are done. Available medical evidence are summarized, and grading of evidence is made, until a draft recommendation is developed. Draft guidelines are then reviewed by stakeholders until a final guideline is produced and published.

In this special issue, we bring you outputs from this guideline development process - four relevant documents on COVID-19, Pediatric Community Acquired Pneumonia (in collaboration with the Philippine Academy of Pediatric Pulmonologists), Leptospirosis, and Pediatric Immunization (prepared by the National Institutes of Health-Institute of Clinical Epidemiology and funded by the Department of Health).

The guideline development process is imperfect. Some shortcomings include paucity of evidence on certain questions, presence of potential conflicts of interest among members of the committee, limitations in funding, and even time. The major advantage is access to a summarized wealth of evidence on a specific topic to enhance physician expertise, improve healthcare quality, and reduce healthcare cost. Guidelines can also influence health policies so that underrecognized health concerns and services can be made available to the majority.

Guidelines should be used with the best interest of the individual patient in mind. They help to improve patient care quality. The complex medical decision making process done by the physician however, should not be limited by simplistic algorithms suggested by guidelines.

Correspondence:
Dr. Carmina A. Delos Reyes
Email: pidsp2009@yahoo.com
## DECLARATION OF CONFLICTS OF INTEREST

In the interest of transparency, we are providing disclosures of potential conflicts of interest, current positions and professional affiliations of the members of the PIDSP Editorial Board 2022-2024:

<table>
<thead>
<tr>
<th>Editor in Chief</th>
<th>Current Positions/Affiliations</th>
</tr>
</thead>
</table>
| Dr. Carmina A. Delos Reyes, MD | 1. Consultant, Division of Infectious and Tropical Diseases in Pediatrics, Department of Pediatrics, University of the Philippines Philippine General Hospital and Clinical Associate Professor, Department of Pediatrics, University of the Philippines College of Medicine  
2. Residency Training Officer, Amang Rodriguez Memorial Medical Center  
3. Co-Chair, Research Committee, Pasig City General Hospital  
4. Chair, Education Committee, Philippine Foundation for Vaccination  
5. Member, Philippine Guidelines on Pediatric Health Examination (PHEX 3) CPG on Pediatric Immunization  
6. Member, National Antibiotic Guidelines Committee  
7. Member, Philippine Pediatric Society Committee on TB Handbook in Children  
8. Active Consultant, Marikina Valley Medical Center, Metro Antipolo Hospital and Medical Center  
No potential sources of conflict to declare |

| Dr. Arlene S. Dy-Co, MD | 1. Section Head, Pediatric Infection Diseases, National Children’s Hospital  
2. Active Consultant, World Citi Medical Center and St. Luke’s Medical Center, Quezon City  
No potential sources of conflict to declare |

<table>
<thead>
<tr>
<th>Advisor</th>
<th>Current Positions/Affiliations</th>
</tr>
</thead>
</table>
| Dr. Cecilia Maramba-Lazarte, MD | 1. Director, Institute of Herbal Medicine, National Institutes of Health, University of the Philippines Manila  
2. Professor 12 and Assistant Chair for Research, Department of Pharmacology and Toxicology, University of the Philippines College of Medicine  
3. Clinical Professor, Division of Infectious and Tropical Diseases in Pediatrics, Department of Pediatrics, University of the Philippines Philippine General Hospital  
4. President, Philippine Association of Medical Journal Editors  
5. Chair, Adverse Event Committee, Research Ethics Board, University of the Philippines Manila  
6. Member, Health Technology Assessment Core Committee  
7. Member, National Antibiotic Guideline Committee  
8. Member, Board of Directors, Daniel dela Paz Foundation  
9. Member, Board of Directors, University of the Philippines Medical Foundation  
10. Member, Board of Trustees, Health Alternatives for Total Human Development Institute, Inc.  
No potential sources of conflict to declare |

<table>
<thead>
<tr>
<th>Editorial Board Member</th>
<th>Current Positions/Affiliations</th>
</tr>
</thead>
</table>
| Dr. Mary Ann Bunyi, MD | 1. Deputy Executive Director of Education, Training and Research Services; Active consultant and trainer of the Pediatric Infectious Disease section, Philippine Children’s Medical Center  
2. Immediate past president of Pediatric Infectious Disease Society of the Philippines  
3. Assistant Professor, Department of Microbiology, College of Medicine, Pamantasan ng Lungsod ng Maynila  
4. Member, Advisory Board of Pfizer for Ceftazidime-avibactam, conjugated pneumococcal vaccine and conjugated meningococcal vaccine  
5. Speaker for Sanofi Philippines for some vaccine products  
No potential sources of conflict to declare |

| Dr. John Andrew Camposano, MD | 1. Medical Specialist – Western Visayas Medical Center, Western Visayas Sanitarium  
2. Visiting Consultant – West Visayas State University Medical Center, Medicus Medical Center, Holy Mary Women and Children’s Medical Center  
No potential sources of conflict to declare |
<table>
<thead>
<tr>
<th>Name</th>
<th>1.</th>
<th>2.</th>
<th>3.</th>
<th>No potential sources of conflict to declare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Mary Antoinette Cuady-Madrid, MD</td>
<td>Active Consultant, Section of Pediatric Infectious Disease, Philippine Children’s Medical Center</td>
<td>Assistant Professor, Department of Microbiology and Parasitology, College of Medicine, Pamantasan ng Lungsod ng Maynila</td>
<td>Ceftazidime/avibactam Pediatric Use Advisory Board (Medical Affairs), Pfizer</td>
<td></td>
</tr>
<tr>
<td>Dr. Xenia Catherine Fabay, MD</td>
<td>Clinical Documentation Consultant, AE &amp; Associates, LLC</td>
<td>Contractor for The Medical Group-Kaiser Permanante, Encounter Information Operations, Diagnosis Validation Team, Oakland, California</td>
<td>No potential sources of conflict to declare</td>
<td></td>
</tr>
<tr>
<td>Dr. Elizabeth Gallardo, MD</td>
<td>Professor, Department of Pediatrics and Microbiology and Parasitology, Saint Louis University, School of Medicine, Baguio City</td>
<td>Member, Pediatric Residency Training Committee, Saint Louis University - Sacred Heart Medical Center, Baguio City</td>
<td>Part of speakers bureau of Pfizer vaccines, Sanofi-Pasteur, Pedriatrica and MSD vaccines</td>
<td>No potential sources of conflict to declare</td>
</tr>
<tr>
<td>Dr. Fatima Gimenez, MD</td>
<td>President, Pediatric Infectious Disease Society of the Philippines</td>
<td>Training Officer, Philippine Children’s Medical Center</td>
<td>Chair, Immunization Committee, Philippine Pediatric Society</td>
<td>No potential sources of conflict to declare</td>
</tr>
<tr>
<td>Dr. Jonathan Lim, MD</td>
<td>Vice chair, Dept of Pediatrics, Chong Hua Hospital</td>
<td>Alternate Member, Chong Hua Hospital Institutional Review Board</td>
<td>No potential sources of conflict to declare</td>
<td></td>
</tr>
<tr>
<td>Dr. Sarah Makalinaw, MD</td>
<td>Member, Research Committee, Institute of Pediatrics; Peer Reviewer, The Medical City Journal; Member, TB Council, The Medical City</td>
<td>Co-Chair, Antimicrobial Stewardship Committee; Member, Research Ethics and Review Committee; Member, Research Committee, Department of Pediatrics, Victor R. Potenciano Medical Center</td>
<td>No potential sources of conflict to declare</td>
<td></td>
</tr>
<tr>
<td>Dr. Francesca Mae Pantig, MD</td>
<td>Visiting Medical Consultant, Department of Pediatrics; Member, Antimicrobial Stewardship (AMS) Committee; Member, Infection Control Committee and STD/HIV-AIDS Committee, Angeles University Foundation Medical Center</td>
<td>Active Consultant, Department of Pediatrics; Chair, Infection Control Committee; Head, Antimicrobial Stewardship (AMS) Committee, Dr. Amando L. Garcia Medical Center, Inc.</td>
<td>Active Consultant, Department of Pediatrics; Chair, Infection Control Committee; Member, Antimicrobial Stewardship (AMS) Committee, AC Sacred Heart Medical Center</td>
<td>No potential sources of conflict to declare</td>
</tr>
<tr>
<td>Dr. Paul Sherwin Tarnate, MD</td>
<td>Clinical Research Investigator, COVID-19 Vaccine Clinical Trials</td>
<td>Vaccine Study Group, Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila</td>
<td>No potential sources of conflict to declare</td>
<td></td>
</tr>
</tbody>
</table>